Actinium Pharmaceuticals, Inc.
ATNM · AMEX
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.09 | 0.03 | -0.01 | 0.03 |
| FCF Yield | -12.67% | -12.35% | -15.08% | -14.63% |
| EV / EBITDA | 0.41 | 2.24 | 0.87 | 4.39 |
| Quality | ||||
| ROIC | -11.40% | -13.42% | -26.78% | -10.82% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 50.00% |
| Cash Conversion Ratio | 1.23 | 0.78 | 0.48 | 0.86 |
| Growth | ||||
| Revenue 3-Year CAGR | 448,040.47% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -17.30% | 28.81% | -31.70% | 51.97% |
| Safety | ||||
| Net Debt / EBITDA | 9.18 | 8.79 | 4.06 | 9.77 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -3,403.24 | -2,862.44 | 0.00 |